Table 1 Clinical characteristics of... | American Society of Hematology

Table 1

Clinical characteristics of patient population

Pt no.	Age at dx, y	Peak eos/mm³	End organ manifestations	Prior therapy*	Initial imatinib dose, mg	Months to imatinib de-escalation	Months to imatinib interruption
1	35	18 877	Mucosal ulcerations, dermatitis, anemia, thrombocytopenia, splenomegaly	Pred, HU, IFN, SCH55700	400	21	NA
2	47	7 220	Mucosal ulcerations, dermatitis, splenomegaly	Pred, HU, IFN, SCH55700	400	14	29
3	35	24 500	Fatigue, splenomegaly	HU	400	9	25
4	45	24 000	Restrictive lung disease, dermatitis, splenomegaly	None	400	10	28
5	34	5 395	Lymphomatoid papulosis, dermatitis	None	400	7	19
6	32	7 400	Endomyocardial fibrosis, anemia, thrombocytopenia, hepatosplenomegaly	None	300	NA	NA
7	44	200 000	Endomyocardial fibrosis, anemia, thrombocytopenia, splenomegaly, dermatitis, restrictive pulmonary disease	Pred, HU, IFN, CyA	400	NA	NA

Pt no.	Age at dx, y	Peak eos/mm³	End organ manifestations	Prior therapy*	Initial imatinib dose, mg	Months to imatinib de-escalation	Months to imatinib interruption
1	35	18 877	Mucosal ulcerations, dermatitis, anemia, thrombocytopenia, splenomegaly	Pred, HU, IFN, SCH55700	400	21	NA
2	47	7 220	Mucosal ulcerations, dermatitis, splenomegaly	Pred, HU, IFN, SCH55700	400	14	29
3	35	24 500	Fatigue, splenomegaly	HU	400	9	25
4	45	24 000	Restrictive lung disease, dermatitis, splenomegaly	None	400	10	28
5	34	5 395	Lymphomatoid papulosis, dermatitis	None	400	7	19
6	32	7 400	Endomyocardial fibrosis, anemia, thrombocytopenia, hepatosplenomegaly	None	300	NA	NA
7	44	200 000	Endomyocardial fibrosis, anemia, thrombocytopenia, splenomegaly, dermatitis, restrictive pulmonary disease	Pred, HU, IFN, CyA	400	NA	NA

All patients were male.

dx indicates diagnosis; eos, eosinophil count; HU, hydroxyurea; IFN, interferon; SCH55700, monoclonal antibody to interleukin 5; CyA, cyclosporin A; and NA, not applicable.